Tagged with AstraZeneca

Global AstraZeneca recently announced plans to continue investing in China, the company’s second largest market after the United States, with the construction of a production facility that will serve as its regional headquarters in Qingdao, Shandong. The plans were announced during the third Qingdao Multinationals Summit. “To further promote the development…

China Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential tool to shifting away from the country’s zero-COVID policy – is under threat from new mutations of the virus. Other…

Global The top COVID-19 Vaccines by revenue in 2021 and sales projections for 2022 based on Airfinity’s COVID-19 Vaccine Market Revenue Forecast 2022. Pfizer/BioNTech’s vaccine stands to make USD 42.69 billion in 2022, while Moderna’s product has projected sales of USD 25.71 billion. Projected USD 3.97 billion sales for Russia’s Sputnik…

Saudi Arabia Sameh ElFangary, Country President for GCC and Pakistan at AstraZeneca, highlights AstraZeneca’s alignment with, and commitment to, Saudi Arabia’s Vision 2030 and the opportunities that the Vision is creating. ElFangary also explains the significance of a new memorandum of understanding to create a clinical research hub in Riyadh and how…

Global The oncology field has exploded in the past 20 years and pharma companies now have a wide range of approaches available to them as they look to identify, treat, and in some cases even cure, cancer patients. Here, five industry experts weigh in on the exciting new tools and technology…

UK After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back at the reputational hits (some fair and some less so) that the firm has suffered over the past 12 months…

UK The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over 1,000 new jobs at its facilities in Northern Ireland over the next three years.   AstraZeneca to create dedicated Covid…

China The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli Lilly, Merck & Co., Novartis, Novo Nordisk, and Sanofi have achieved China growth in the first half of the year despite pricing squeezes on their mature brands; and why Bayer sees huge growth potential…

Singapore AstraZeneca (AZ)’s country president for Singapore, Vinod Narayanan, outlines the challenges of taking the reins at an affiliate against the backdrop of a pandemic and how the Anglo-Swedish company’s quest for a COVID-19 vaccine has opened up new partnership opportunities in the region. Narayanan also touches on Singapore’s open ecosystem…

China The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta; the Big Pharma losers from the latest round of price cuts for off-patent drugs; Lonza’s new investment in Chinese API manufacturing expansion; and Dingdang Health’s recent USD 220 million financing round.   Yescarta…

Switzerland AstraZeneca’s recently arrived Switzerland country president, Katrien de Vos, gives her first impressions of the Swiss market and how she hopes to build upon the affiliate’s strong performance. de Vos also touches on access challenges (and how to surmount them) as well as AstraZeneca Switzerland’s role in bringing the company’s…

UK Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of COVID-19 and Brexit seem set to muddy the waters of cross-border pharma trade for some time to come.   Five…